A Study of SHR-A1811 in Subjects With Ovarian Cancer
A phase 3 trial of Trastuzumab rezetecan, Paclitaxel / nab-paclitaxel, Gemcitabine in ovarian cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
Overview
A Study of SHR-A1811 in Subjects With Ovarian Cancer is a phase 3 interventional study registered as NCT06828354 by Jiangsu HengRui Medicine Co., Ltd., with 300 participants planned, started 2025-03-13 and due to reach its primary completion in 2027-05. Interventions recorded: SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection, Gemcitabine Hydrochloride for Injection, Topotecan Hydrochloride for Injection. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Gemcitabine, Paclitaxel / nab-paclitaxel.
- TrialA Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialStudy to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Shares Topotecan, Gemcitabine, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialAn Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can
Shares Topotecan, Gemcitabine, Paclitaxel / nab-paclitaxel, Ovarian cancer.
- TrialA Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialA Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialPhase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals.
- TrialA Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.